Issue link: https://viewer.e-digitaledition.com/i/553463
T HE MOST COMMON HAIs, includ- ing surgical site infections, Clostridium difficile (C-diff) infections, urinary tract infec- tions and pneumonia, impact about 5 percent of hospitalized patients. Those who contract these infections have much higher mortality rates than other patients. Among trauma patients, for instance, people who acquired sepsis in the hospital were six times more likely to die, and those who acquired other HAIs were 50 to nearly 100 percent more likely to die than similar patients who did not acquire HAIs, according to a 2011 study in Archives of Surgery (now JAMA Surgery). HAIs also create signifi cant costs: $45,000 per case for a central-line infection and $11,000 for each case of C-diff, for instance, according to a 2013 study in JAMA Internal Medicine. "There are two aspects to [finding solutions to HAIs]," says Ruth Carrico, PhD, RN, FSHEA, CIC, who leads a C-diff vaccination trial at the University of Louisville. "Innovation may involve pushing the envelope so best practices are fully implemented. On the other side of implementation is coming up with new ideas: What are the implementations we need to address? What are the strategies we have yet to appreciate?" Copper to the Rescue? One 2013 study, published in Infection Control and Hospital Epidemiology, examined whether copper could reduce the spread of HAIs in the ICU setting. Researchers replaced materials typically used on high-traffi c surfaces — surfaces such as touchscreens, visitors' chair rails, bed rails and IV poles — with a copper alloy. Compared with similar residents of unmodifi ed rooms, ICU patients in rooms where the alloy was used developed sig- nifi cantly fewer HAIs. However, overall patient mortality and length of stay were about the same for both groups. Studying how such organisms travel through the environment, researchers in Oxford, England, have found C-diff may be less related to symptomatic hospital patients than is frequently assumed. Observing 1,200 patients with C-diff and performing whole-genome sequencing on C-diff isolates from those patients, they learned that only 35 percent of their C-diff isolates were related to previous hospital cases. Forty-fi ve percent were "genetically distinct from all other cases." Furthermore, of those patients whose C-diff isolates appeared to be related to previous hospital cases of the disease, only about half reported any possible hospital or community exposure to another patient. A Stick in Time Sanofi Pasteur is sponsoring a trial of a vaccination for C-diff in conjunction with healthcare organizations and universities at 190 locations around the globe. "Research is not only involved in treat- ment," says Carrico, one of the trial leaders at the University of Louisville. "We are trying to think about preventing disease from happening in the fi rst place." ■ VACCINE TRIALS, WHOLE-GENOME SEQUENCING AND EVEN NEW HOSPITAL FURNISHINGS MAY HELP SCIENTISTS REDUCE THE 1.7 MILLION HEALTHCARE-ASSOCIATED INFECTIONS (HAIs) THAT OCCUR IN THE UNITED STATES ANNUALLY. to Thwart Healthcare-associated Infections INNOVATING By Jennifer Webster to Thwart Healthcare-associated Infections INNOVATING By Jennifer Webster ++++++++++++++++++++++++++++++ + +++ + +++ ++++++++++++++++++++++++++++++ PRACTICE MANAGEMENT ❯ 1 8 | Lower Hudson/Bronx MD NEWS ■ M D N E W S . CO M

